Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024 at 07:03 AM EST
The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
